Trial · NCT03655262
Treating Phobia With Multivoxel Neuro-reinforcement
NCT03655262, Not applicable, Completed, University of California, Los Angeles; results first posted 2023-12-27
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Treating Phobia With Multivoxel Neuro-reinforcement. Trials, record NCT03655262. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03655262
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Treating Phobia With Multivoxel Neuro-reinforcement
- NCT number
- NCT03655262
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 23 participants, actual
- Lead sponsor
- University of California, Los Angeles
- Conditions
- Phobia
- Interventions
- Unconscious Neuro-reinforcement
- First posted
- 2018-08-31
- Last updated
- 2024-02-02
- Results first posted
- 2023-12-27
Source ClinicalTrials.gov
Registered outcomes5
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Amygdala Reactivity | 10 days (measured at pre-treatment and post-treatment) | The neural measure of difference in amygdala reactivity (measured by fMRI) to target phobic animals compared to control phobic animals from pre-treatment to post-treatment. Lower numbers (i.e. more negative numbers) indicate greater amygdala decrease and and better outcomes. |
| Primary | Subjective Fear Post-treatment Minus Pre-treatment | 10 days (measured at pre-treatment and post-treatment) | Subjective Fear Ratings of images of targeted phobic stimuli Minimum score of 0, Maximum score of 180, higher scores mean worse outcome. |
| Secondary | Skin Conductance Response: Physiological Arousal Post-treatment Minus Pre-treatment | 10 days (measured at pre-treatment and post-treatment) | Skin conductance to image presentation of targeted phobic stimuli post-treatment minus pre-treatment |
| Secondary | Fear Survey Schedule | 10 days (measured at pre-treatment and post-treatment) | Subjective fear ratings of a list of typical phobic stimuli Minimum score of 40, maximum of 200, higher scores mean worse outcome. |
| Secondary | Stroop Task Post-treatment Minus Pre-treatment | 10 days (measured at pre-treatment and post-treatment) | Measure of preferential allocation of attentional resources measured in reaction time (seconds) for visual presentation of the targeted phobic stimulus |
Source ClinicalTrials.gov
Outcomes5
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Change in Amygdala Reactivity | 10 days (measured at pre-treatment and post-treatment) | Beta Coefficient | MEAN | |
| PRIMARY | Subjective Fear Post-treatment Minus Pre-treatment | 10 days (measured at pre-treatment and post-treatment) | units on a scale | MEAN | |
| SECONDARY | Skin Conductance Response: Physiological Arousal Post-treatment Minus Pre-treatment | 10 days (measured at pre-treatment and post-treatment) | Square Rooted Microsiemens | MEAN | |
| SECONDARY | Fear Survey Schedule | 10 days (measured at pre-treatment and post-treatment) | units on a scale | MEAN | |
| SECONDARY | Stroop Task Post-treatment Minus Pre-treatment | 10 days (measured at pre-treatment and post-treatment) | Seconds | MEAN |
Source ClinicalTrials.gov
Results by group15
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change in Amygdala Reactivity | 1 Session | -.691 | Standard Deviation .796 | Beta Coefficient | |
| Change in Amygdala Reactivity | 3 Sessions | -.827 | Standard Deviation 1.620 | Beta Coefficient | |
| Change in Amygdala Reactivity | 5 Sessions | -.278 | Standard Deviation 1.682 | Beta Coefficient | |
| Subjective Fear Post-treatment Minus Pre-treatment | 1 Session | 0.32 | Standard Deviation 0.32 | units on a scale | |
| Subjective Fear Post-treatment Minus Pre-treatment | 3 Sessions | -0.03 | Standard Deviation 0.37 | units on a scale | |
| Subjective Fear Post-treatment Minus Pre-treatment | 5 Sessions | 0.43 | Standard Deviation 0.97 | units on a scale | |
| Skin Conductance Response: Physiological Arousal Post-treatment Minus Pre-treatment | 1 Session | -0.010 | Standard Deviation 0 | Square Rooted Microsiemens | |
| Skin Conductance Response: Physiological Arousal Post-treatment Minus Pre-treatment | 3 Sessions | -0.097 | Standard Deviation 0.181 | Square Rooted Microsiemens | |
| Skin Conductance Response: Physiological Arousal Post-treatment Minus Pre-treatment | 5 Sessions | -0.030 | Standard Deviation 0.192 | Square Rooted Microsiemens | |
| Fear Survey Schedule | 1 Session | -2.46 | Standard Deviation 1.13 | units on a scale |
1 to 10 of 15Source ClinicalTrials.gov
See all 15 results by groupParticipant flow9
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | 1 Session | 7 | |
| Overall Study | STARTED | 3 Sessions | 8 | |
| Overall Study | STARTED | 5 Sessions | 8 | |
| Overall Study | COMPLETED | 1 Session | 7 | |
| Overall Study | COMPLETED | 3 Sessions | 8 | |
| Overall Study | COMPLETED | 5 Sessions | 7 | |
| Overall Study | NOT COMPLETED | 1 Session | 0 | |
| Overall Study | NOT COMPLETED | 3 Sessions | 0 | |
| Overall Study | NOT COMPLETED | 5 Sessions | 1 |
Source ClinicalTrials.gov
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals9
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | 1 Session | 0 | 7 |
| Total, all-cause mortality | 3 Sessions | 0 | 8 |
| Total, all-cause mortality | 5 Sessions | 0 | 8 |
| Total, other adverse events | 1 Session | 0 | 7 |
| Total, other adverse events | 3 Sessions | 0 | 8 |
| Total, other adverse events | 5 Sessions | 0 | 8 |
| Total, serious adverse events | 1 Session | 0 | 7 |
| Total, serious adverse events | 3 Sessions | 0 | 8 |
| Total, serious adverse events | 5 Sessions | 0 | 8 |
Source ClinicalTrials.gov
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| R61MH113772 | Treating Phobia with Multivoxel Neuro-reinforcement | CRASKE, MICHELLE G | UNIVERSITY OF CALIFORNIA LOS ANGELES | NATIONAL INSTITUTE OF MENTAL HEALTH | 2018 to 2019 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests1
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as |
|---|---|
| Stroop Color-Word Test | Secondary outcome |
Source ConductCognition
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03655262
GET https://conductscience.org/api/trials/v1/NCT03655262/registered